Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran

被引:0
作者
Zahra Goudarzi
Farhad Lotfi
Zhila Najafpour
AliAkbar Hafezi
Marzieh Alizadeh Zakaria
Khosro Keshavarz
机构
[1] Shiraz University of Medical Sciences,Health Human Resources Research Center, School of Health Management and Information Sciences
[2] Shiraz University of Medical Sciences,Emergency Medicine Research Center
[3] Ahvaz Jundishapur University of Medical Sciences,Department of Health care Management, School of Public Health
[4] Shiraz University of Medical Sciences,Department of Radiation Oncology, School of Medicine
[5] Shiraz University of Medical Sciences,Student Research Committee, School of Management and Medical Information Sciences
[6] Shiraz University of Medical Sciences,Health Human Resources Research Center, Department of Health Economics, School of Health Management and Information Sciences
来源
BMC Urology | / 24卷
关键词
Cost-effectiveness; Enzalutamide; Prostate cancer resistant to castration; Abiraterone;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 197 条
  • [1] Wang L(2022)Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019 Front Public Health 10 811044-5
  • [2] Lu B(2018)The incidence of prostate cancer in Iran: a systematic review and meta-analysis Prostate Int 6 41-65
  • [3] He M(2022)Targeted approaches in Metastatic Castration-resistant prostate Cancer Which Data? Cancers 14 4189-23
  • [4] Wang Y(2022)Androgen deprivation therapy in high-risk localized and locally advanced prostate cancer Cancers 14 1803-22
  • [5] Wang Z(2022)Sequencing of systemic therapies in the management of advanced prostate Cancer in India: a Delphi-based Consensus Oncol Therapy 10 143-2005
  • [6] Du L(2013)Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 213-97
  • [7] Hassanipour S(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-80
  • [8] Fathalipour M(2011)Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 1995-19
  • [9] Salehiniya H(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 1187-40
  • [10] Mosillo C(2016)Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide Clin Pharmacokinet 55 1369-78